{"contentid": 488044, "importid": NaN, "name": "ElevateBio bags huge $525 million in Series C round", "introduction": "Cell and gene therapy incubator ElevateBio has raised $525 million in a Series C financing.", "content": "<p>Cell and gene therapy incubator ElevateBio has raised $525 million in a Series C financing.</p>\n<p>The Boston-based firm claims to be changing the way the field advances with technologies including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering.</p>\n<p><span class=\"pullQuote\">\"Accelerating innovation requires next-generation technology, analytics, and production capabilities\"</span>With this financing, ElevateBio will continue to develop and expand its technology platforms, build upon its network of process development and GMP manufacturing capacity, and advance an increasing number of industry partnerships, while also continuing to develop its own cell and gene therapies.</p>\n<p>The financing was led by Matrix Capital Management, joined by additional new investors SoftBank Vision Fund 2 and Fidelity Management and Research Company alongside ElevateBio&rsquo;s existing backers.</p>\n<p><span class=\"il\">ElevateBio</span>&nbsp;raised&nbsp;$150 million Series A in May 2019<strong>&nbsp;</strong>upon launch of the company, and&nbsp;$170 million Series B in March 2020,&nbsp;to which an additional $23 million was added through a second close, bringing the Series B total to $193 million.</p>\n<p>Investors evidently see this as a growth area. There are nearly a thousand cell and gene therapies in development targeting a broad range of diseases, yet as of February 2020, only nine were approved in the USA.</p>\n<p>Despite the small number of approved therapies, the global cell and gene therapy market is expected to reach nearly $50 billion by 2027. The US Food and Drug Administration predicts that by 2025, the agency will be approving 10 to 20 cell and gene therapy products each year based on an assessment of the current pipeline and the clinical success rates of these products.</p>\n<p>David Hallal, chairman and chief executive of ElevateBio, said: &ldquo;ElevateBio has created the first fully-integrated technology company exclusively focused on cell and gene therapy, disrupting the current paradigm by providing end-to-end capabilities that enable partners a strategic advantage in the market and, ultimately, meet the urgent need of patients and families suffering with life-threatening and devastating diseases.</p>\n<p>&ldquo;While we see remarkable breakthroughs in the earliest days of the cell and gene therapy revolution, accelerating innovation requires next-generation technology, analytics, and production capabilities to deliver therapies better, faster, and cheaper. We are poised to power the field today and for many decades to come.&rdquo;</p>", "date": "2021-03-15 16:39:00", "meta_title": NaN, "meta_keywords": "gene, cell, ElevateBio, technology, therapy, million, Series, financing, company, therapies, bags, huge, raised, capabilities, accelerating, production", "meta_description": "Cell and gene therapy technology company ElevateBio has raised $525 million in a Series C financing.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-15 15:53:27", "updated": "2021-03-15 16:39:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/elevatebio-bags-huge-525-million-in-series-c-round", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "elevate_bio_large.png", "image2id": "elevate_bio_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Genetics, Genomics", "topic_tag": "Business Financing, Research", "geography_tag": "USA", "company_tag": "ElevateBio", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-15 16:39:00"}